gene rearrangement, which is caused by the translocation or inversion of chromosome 2p, is an important patient subset of lung cancer. The prevalence of ALK positive patients has been reported to range from 3% to 7% in advanced NSCLC (3) (4) (5) (6) , and 2.3% to 8.6% in early stage NSCLC (7) (8) (9) (10) (11) (12) (13) (14) . ALK positivity is correlated with adenocarcinoma histology, particularly the solid and signet ring pattern; never or light/former smoking status; younger age; and wild type for EGFR or KRAS gene mutation (5, (15) (16) (17) (18) (19) .
ALK was first discovered in 1994 as a fusion oncogene with nucleophosmin (NPM) in a subset of anaplastic largecell lymphomas (ALCLs) (20) . However, it was not until 12 years ago that interest in ALK surged after the discovery of a novel ALK fusion-echinoderm microtubule-associated protein-like 4 (EML4)-ALK, a somatic gene rearrangement found in a small portion of Japanese lung cancers (21) . EML4-ALK is formed by an inversion occurring on the short arm of chromosome 2 involving the genes encoding ALK (2p23) and EML4 (2p21) with variants 1, 2, and 3a/3b (22, 23) . The three major variants (v1: E13; A20, v2: E20; A20, and v3; E6; A20) account for more than 90% of lung cancers associated with EML4-ALK. In addition to EML4-ALK, several other ALK fusions have been reported, including TRK-fused gene (TFG)-ALK , kinesin family member 5B (KIF5B)-ALK and kinesin light chain 1 (KLC1)-ALK (15, 24, 25) . At the cellular level, ALK regulates canonical signaling pathways that are shared with other receptor tyrosine kinases (RTK) including RAS-mitogenactivated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)-AKT, and JAK-STAT pathways (26) . In ALK rearrangements, 5' end partners such as EML4 and NPM are fused to the intracellular tyrosine kinase domain of ALK. The domains in the partner proteins promote dimerization and oligomerization of the fusion proteins, inducing constitutive activation of the ALK kinase and its downstream signaling pathways. This leads to uncontrolled cellular proliferation and survival. The EML4-ALK fusion gene possesses powerful oncogenic activity, both in vivo and in vitro (21, 27) , which might result in poor prognosis of NSCLC. However, several published studies show the conflicting results about the prognostic value of ALK rearrangement in NSCLC (7) (8) (9) (10) (11) (12) (13) (14) (28) (29) (30) (31) . Tantraworasin (10) , Paik (8) , Fukui (29) , and Ohba (12) , demonstrated that ALK positivity was not correlated with prognosis. Conversely, five reports revealed that patients with ALK rearrangement NSCLC had a shorter DFS (7, 9, 13, 14, 28) . In contrast, Blackhall et al. reported superior RFS and OS in patients with ALK positive early-stage NSCLC (11) . Preclinical studies demonstrate that ALK-driven lung cancers are addicted to ALK and highly sensitive to ALK inhibition (27, 32) , indicating that ALK rearrangement is a predictive factor for the therapeutic effect of ALK inhibitors. Additionally, several ALK inhibitors are already approved for the first line treatment of advanced stage ALK-positive NSCLC due to their encouraging therapeutic effect (33) (34) (35) (36) . The prognostic value of ALK rearrangement will help guide management and formulate statistical assumptions in the design of future ALK inhibitor-based adjuvant clinical trials. However, the prognostic significance of ALK rearrangement remains unclear and further investigation is needed.
The major objectives of the present study are not only to compare the clinical outcomes of ALK-positive versus ALK-negative completely resected stage I-IIIA lung adenocarcinoma patients, but also to explore the correlation of ALK rearrangement with clinical characteristics.
Methods

Study population and data collection
In our study, 2,103 patients with pathological stage I-IIIA lung adenocarcinoma who underwent complete resection in Shanghai Chest Hospital between July 2013 and December 2014, with at least 4 years of follow-up were included in the study. The patients who received neoadjuvant chemotherapy or radiotherapy were excluded. The patients did not receive ALK-targeted therapy before tumor recurrence in our study cohort. Histological types of lung adenocarcinoma are determined according to 2015 WHO classification of lung adenocarcinoma. The predominant pattern was defined as the pattern with the largest percentage. Lung cancer pathologic staging of the patients was based on the 8th edition of the TNM classification. All patients' clinicopathologic characteristics were collected from the medical recording system. This study was approved by Ethics Committee of Shanghai Chest Hospital Jiao Tong University. 
Detection of ALK rearrangement
Immunohistochemistry (IHC) was performed for all patients on 5-μm thick formalin-fixed paraffin-embedded surgical specimens with the fully-automated Ventana IHC system using the D5F3 anti-ALK rabbit monoclonal primary antibody in a Bech-mark XT staining module (Ventana Medical Systems, Illkirch Graffenstaden, France).
The ALK status was described by a binary scoring system, either ALK positive or ALK negative. The histopathologic types and ALK status were evaluated independently by two experienced pathologists of Shanghai Chest Hospital.
Clinical outcomes and statistical analysis
Clinical outcomes were presented by overall survival (OS), defined as the time interval from date of surgery to death from any cause; disease-free survival (DFS), defined as the time from date of surgery to disease recurrence or death from any cause. If recurrence or death was not observed, the censoring date was the last day of follow-up. Both OS and DFS were calculated in months. Statistical analyses were performed using SPSS ® , version 24.0 (SPSS Inc., Chicago, IL, USA). Comparison of clinical characteristics according to ALK status was performed using Mann-Whitney U tests (continuous variables) and chisquare tests or Fisher's exact tests (categorical variables).
Association between time-to-event outcomes and ALK status is only explored in ALK matched cohort. For this cohort, survival was estimated by the Kaplan-Meier method and compared using the log-rank test. The median followup time was estimated using the reverse censoring method for OS. Cox proportional hazards regression analysis was used to calculate the hazard ratio (HR) and 95% confidence interval (CI). Multivariable Cox regression, with the backward elimination procedure (removal criterion of 10%), was used to choose the best model for DFS and OS, examining characteristics including sex, age at surgery, smoking status, pathologic tumor stage (pT stage), pathologic nodal stage (pN stage), adenocarcinoma subtypes and ALK status. In all analyses, two-tailed P<0.05 was considered statistically significant.
Propensity score matching (PSM)
PSM was used to control for confounding effects of known predictors for lung cancer progression or recurrence. PSM was carried out in stage IA, IB, IIA, IIB, IIIA cohort respectively to guarantee the exact balance of pathologic stage, which was considered to be the most important prognostic factor, between ALK positive and ALK negative patients in the matched cohort. Propensity scores for all patients were calculated by using a multiple logistic regression with the following covariates: age, sex, type of surgery, histological subtypes and pleura invasion status. In the ALK matched cohort, all 81 ALK positive patients were matched 1:1 with 81 ALK negative patients. The clinical characteristics baseline before and after PSM were shown in Table S1 .
Follow up
The follow-up data of the matched cohort were obtained by official contact with patients or their relatives by telephone or collected from hospital records. In the matched cohort of 162 patients, seven patients lost contact after surgery in the ALK positive group, and 8 patients in the ALK negative group. The workflow of the determination of the ALK status and the populations identified is depicted in Figure 1 .
Routine examinations, such as a plain chest X-ray; computed tomography scan of the thorax, head, and abdomen; and ultrasound of neck and abdomen, were generally performed every 3 months for the first 2 years after surgery and every 6 months after that for 5 years. After 5 years, the patients were assessed annually. Bone scans were performed as clinically indicated on the basis of bone pain. Positron emission tomography and bronchoscopy with biopsy were performed at the treating physician's discretion.
The follow-up period was completed in December 2018 or to the death date of patients. The median follow-up was 55.3 months (interquartile range, 51.6 to 60.2 months).
Results
Clinicopathologic characteristics of ALK positive patients
The clinicopathologic characteristics of 2,103 completelyresected stage I-IIIA lung adenocarcinoma patients are shown in Table 1 . Eighty-one (3.9%) of the 2,103 patients were ALK positive. Eight hundred and ninety patients (42.3%) were male, and 1,213 (57.7%) were female; age (year) at surgery ranges from 24 to 83. A total of 1,840 (87.5%) were never-smokers, 252 (12.0%) were smokers, and 11 (0.5%) patients' smoking status were unknown.
Tumor size (cm) ranged from 0.2 to 15.0. The pathologic stage was stage I in 1,639 patients (77.9%), stage II in 210 (10.0%), and stage IIIA in 254 (12.1%). Invasive adenocarcinoma is the only histopathologic subtypes of the whole cohort with lepidic predominant, acinar predominant, papillary predominant, micropapillary predominant, and solid predominant subtypes present in 114 (5.4%), 1,139 (54.2%), 525 (25.0%), 16 (0.8%), and 179 (8.5%) patients, respectively, and variants of invasive adenocarcinoma in 130 patients (6.2%). Pleura invasion occurred in 571 (27.2%) patients.
ALK positivity was significantly associated with younger age (median age, 53 years in the ALK positive group vs. 60 years in the ALK negative group; P<0.001), solid predominant adenocarcinoma (P<0.001), variants of invasive adenocarcinoma (P<0.001), higher frequency of pleura invasion (P=0.040), smaller tumor size(median size, 1.8 cm in the ALK positive group vs. 2.0 cm in the ALK negative group; P=0.014), mediastinal lymph node involvement (N2; P<0.001), later pathologic stage (IIIA; P=0.001) ( Table 1) .
However, there were no significant associations between ALK status and other factors such as sex (P=0.769), smoking status (P=0.911), and pathologic tumor stage (P=0.169) ( Table 1) . Table 1 also shows the clinicopathologic characteristics baseline of the patients after PSM with follow-up information. A total of 81 (3.9%) and 2,022 (96.1%) patients were assigned to the ALK positive group and ALK negative group, respectively. Before PSM, differences were observed in terms of age (P<0.001), adenocarcinoma subtypes (P<0.001), pleura invasion status (P=0.040), tumor size (P=0.014), pN stage (P<0.001), pTNM stage (P<0.001) ( Table 1) ; after PSM, the results were similar between the two groups (P>0.05) except for tumor size (P=0.028) Table S1) , and after the follow-up with 7 patients in the ALK positive group and 8 patients in the ALK negative group losing contact after surgery, the results were still similar between the two groups in the remaining 147 patients even for tumor size (P>0.05; Table 1 ).
Clinicopathologic characteristics baseline data before and after weighting
Prognostic value of the ALK rearrangement in completelyresected stage I-IIIA lung adenocarcinoma
We next evaluated the associations between ALK rearrangement and prognosis in the 147 completelyresected stage I-IIIA lung adenocarcinoma patients. OS of both ALK positive group and ALK negative group
were not yet reached. The log-rank test showed that ALK positivity was not associated with better DFS or OS (DFS, P=0.289; OS, P=0.549; Figure 2 ). We further analyzed the associations between ALK positivity and prognosis by pathologic stage. Table 2 ). And lymph node status was the only prognostic factor of OS (HR: 6.87, 95% CI: 2.66-17.74, P<0.001; Table 2 ). ALK positivity was not associated with better DFS or OS (HR, 0.75; 95% CI: 0.44-1.28; P=0.291; HR: 0.75, 95% CI: 0.30-1.91, P=0.551, respectively; Table 2 ). A multivariate analysis using a Cox proportional hazards model compared survival between ALK positive and ALK negative patients. After adjusting for sex, age, smoking history, adenocarcinoma subtypes, pathologic nodal staging, tumor staging and ALK rearrangement status, the variables that remained significantly associated with decreased DFS were mediastinal lymph node involvement (HR: 5.36, 95% CI: 3.01-9.65, P<0.001; Table 2 ) and solid predominant adenocarcinoma subtype (HR, 2.02; 95% CI: 1.07-3.79; P=0.029; Table 2 ). ALK positivity was not associated with DFS (HR, 0.58; 95% CI: 0.33-1.03, P=0.063; Table 2 ) or OS (HR, 0.61; 95% CI: 0.22-1.67, P=0.334; Table 2 ). These results suggested that ALK rearrangement may not be a prognostic factor in completely resected stage I-IIIA lung adenocarcinoma.
The association of ALK positivity with the initial recurrence site
There were 55 patients with recurrent tumor in the matched cohort with follow up information. And 7 patients detected multiple recurrence sites at the same time and it was hard to find out what was really the initial site of these patients.
In this case, we analyzed the association of ALK positivity with initial recurrence site in the remaining 48 patients with mono recurrence site. As shown in Figure 3 , we found that there was an association between ALK status and liver and lung recurrence, more patients experienced liver recurrence and less experienced lung recurrence in ALK positive group than in ALK negative group [14.3% (3/21) vs. 0% (0/27), P=0.043; 19.0% (4/21) vs. 51.9% (14/27), P=0.020, respectively, Figure 3 ]. There were no differences of other initial recurrence sites including regional lymph nodes, pleura, bone and brain between the two groups.
Discussion
The prevalence of ALK positive patients was 3.9% in our study, consistent with the previous reports looking at unselected populations with mostly advanced adenocarcinoma (3) (4) (5) (6) . Several studies showed a higher prevalence of ALK positivity in younger patients, light smokers or never-smokers, females (15, 16, 28, 30, 37) , and solid predominant adenocarcinoma subtype (14, 38, 39) . In this study, we also found ALK rearrangements were detected more frequently in younger age patients and solid predominant adenocarcinoma subtype. However, ALK positivity showed no association with sex or smoking status, in accord with the results reported in other two studies (10, 14) . Although several previous studies showed that ALK rearrangement was not related to pleural invasion, we found ALK positive patients tend to have pleural invasion more frequently compared with ALK negative patients. A recent meta-analysis concluded that ALK rearrangement was more common in higher pathologic stages (40) , which is in line with our results (IIIA, P=0.001). Furthermore, a previous study found that ALK positive lung cancer showed earlier tumor stage (T1) (P=0.02) (8), whereas it tended to harbor lymph node metastasis in adenocarcinoma (P=0.09), which is also consistent with our results. We revealed that ALK positive patients were more likely to have smaller tumor size (P=0.014) and mediastinal lymph node involvement (P<0.001). However, no significant difference of pathologic tumor stage (P=0.169) between ALK positive and negative group was observed in our study. The prognostic value of ALK rearrangement in early stage NSCLC is controversial. Tantraworasin (10), Paik (8), Fukui (29) , and Ohba (12) , demonstrated that ALK positivity was not correlated with prognosis, which is consistent with our results. Conversely, five reports revealed that patients with ALK rearrangement NSCLC had a shorter DFS after adjusting for main prognostic clinical factors (7, 9, 13, 14, 28) , and two studies showed that ALK positivity was not associated with OS (9, 13) , while other two studies concluded that ALK positive patients had inferior OS (7, 14) . In contrast, Blackhall et al. reported superior RFS and OS in patients with ALK positive early-stage NSCLC (11). To our knowledge, our study is one of the largest data set to report on the outcome of ALK positive patients with stage I to IIIA resected lung adenocarcinoma. Since the significant discrepancies of age, adenocarcinoma subtypes, pTNM stage etc. between the ALK positive group and ALK negative group in the entire cohort, we used PSM method to control the confounding effects of these known prognostic factors for lung cancer recurrence before we compared the prognostic impact of ALK rearrangement. And this is the first report using PSM to reveal that ALK positivity is not associated with DFS or OS. It indicates that ALK rearrangement is not an independent prognostic factor in stage I to IIIA completely resected lung adenocarcinoma patients.
In patients with advanced NSCLC, Shaw et al. found that ALK FISH-positive patients seemed to have similar survival to that of the general population of wild-type patients lacking either ALK rearrangement or EGFR mutation (41) , whereas in a report in patients free of Crizotinib with wild-type EGFR lung adenocarcinoma, ALK rearrangement was associated with longer OS (42) .
As to patients with early stage NSCLC, Chaft et al. found that adjusted for stage ALK rearrangement NSCLC was associated with worse RFS compared to EGFR-mutant, but not when compared to KRAS-mutant (31), In our study, among 73 ALK negative patients in the matched cohort, there were 19 patients with EGFR-mutation,13 with EGFR wild-type and 41 with unknown EGFR mutational status.
Adjusted for main prognostic clinical factors, ALK positive patients showed better DFS compared to both EGFRmutant and EGFR wild-type patients (HR 0.29, 95% CI: 0.14-0.61, P=0.001; HR 0.27, 95% CI: 0.12-0.63, P=0.002, respectively). However, there was no significant difference of DFS between ALK positive patients and EGFR status unknown patients (HR 1.42, 95% CI: 0.61-3.33, P=0.421). These results might attribute to that EGFR status was not regularly tested in our study cohort after surgery. In this case, ALK negative patients who had already experienced recurrence were more likely to undergo the test for EGFR mutation to find out whether they could be treated with EGFR-tyrosine kinase inhibitors (TKI). This might result in significantly higher prevalence of recurrence in patients with clear EGFR status than ALK positive or unknown EGFR status patients in our study cohort. Therefore, it is plausible that the prognostic significance of ALK will alter relative to the EGFR mutational status of ALK-negative patients.
Furthermore, we found that mediastinal lymph node involvement (N2) and solid predominant adenocarcinoma subtype were independent prognostic factors of DFS, while mediastinal lymph node involvement (N2) was the independent prognostic factor of OS. Previous studies have shown that patients with solid predominant adenocarcinoma have poor prognosis (43) (44) (45) , which is consistent with our results. Notably, a higher prevalence of ALK positivity in mediastinal lymph node involvement (P<0.001) and solid predominant adenocarcinoma subtype (P<0.001) was found in our study. When the balance was achieved for these two factors in the matched cohort, there were no significant differences of DFS and OS between ALK positive group and ALK negative group. This result indicated that ALK rearrangement might have an indirect impact on prognosis through its unique biologic features with early nodal metastasis and solid predominant adenocarcinoma subtype. However, when these factors were adjusted using PSM, we found ALK rearrangement was not an independent prognostic factor.
Yang et al. reported that ALK-positive tumors might have an increased risk of brain and liver metastases compared with ALK-negative disease in late stage (28) . In our study, we found that more patients experienced liver recurrence and less experienced lung recurrence in ALK positive group than in ALK negative group. This result indicated that there was an association between ALK status and liver and lung recurrence. But the risk of brain metastases was similar in two groups.
Nevertheless, our study has several limitations. Firstly, we did not analyze the survival of entire cohort and the method PSM has its intrinsic limitation including that there may be other prognostic factors not covered in our regression model. Secondly, fifteen patients were lost to follow-up, although the clinicopathologic characteristics were still balanced between the two groups in the remaining patients. Thirdly, the EGFR or KRAS status were unknown in more than half of ALK negative patients, which made it challenging to analyze the prognostic impact of these genomic subsets. Fourthly, post-recurrence therapy information was lacking in our study and this might affect the OS of patients who experienced recurrence. In addition, since the majority of the patients in our study cohorts were woman and non-smokers, which is not typical of a non-East
Asian population with lung cancer, the applicability of this study's results may be limited in North American/European population.
Conclusions
ALK rearrangement was not an independent prognostic factor in stage I-IIIA lung adenocarcinoma patients, but it significantly correlated with younger age, solid predominant adenocarcinoma, higher frequency of pleura invasion, smaller tumor size, mediastinal lymph node involvement and later pathologic stage. In addition, there was an association between ALK status and liver and lung recurrence, more patients experienced liver recurrence and less experienced lung recurrence with ALK positive tumors than with ALK negative tumors. and the National Science and Technology Major Projects of New Drug Creation (2018ZX09301014-001-003 to S Lu), Shanghai Economic and Information Commission for oncology data platforms (201602010).
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